Needham analysts published a report singling out the diabetes and spine businesses as possible spinoff options for Medtronic (NYSE:MDT).
Mike Matson, David Saxon and Joseph Conway of Needham pointed to previous comments from Medtronic management that indicate the potential for changes in the coming year, with a spinoff of a large business within Medtronic considered to be an option.
